To explore what Australian experts value in breast screening, how these values are conceptualised and prioritised, and how they inform experts' reasoning and judgement about the Australian breast-screening programme.
INTRODUCTION
Mammographic breast screening was first performed in the mid-20th century and became widespread in the 1980s. Public and professional debate about mammography screening began immediately, [1] [2] [3] and intensified after publication of controversial meta-analyses of breast screening randomised controlled trials that suggested lower benefits than originally calculated [4] [5] [6] and significant overdiagnosis. [7] [8] [9] (Throughout this paper, we use overdiagnosis to mean: diagnosis of non-progressive or slowly progressive breast cancer through screening, a diagnosis that does not produce a net benefit for the women diagnosed. We use the term overtreatment to mean the treatment of overdiganosed cancers, treatment which is, by definition, unnecessary [10] [11] [12] ). It was widely hoped 13 that the recently updated review of the evidence by Marmot et al 14 would put an end to the controversy, but disagreements between experts about breast screening persist, particularly around the amount of benefit and the risk of overdiagnosis. 15 Such disagreements can be a challenge
Strengths and limitations of this study
▪ This is the first application of empirical ethics to breast-screening policy and practice outside of consumer studies. ▪ The study has a wide reach, using data from a broad selection of key players in breast screening and covering all important stakeholder groups across the country. ▪ The rich data set and detailed analysis provides a comprehensive picture of how values guide thinking and influence experts' opinions on mammographic screening. ▪ Experts in other jurisdictions, with different organisational structures and different societal values, may express different views. However, since the Australian programme shares much in terms of rationale, purpose and implementation with counterpart programmes in the UK and many European countries, it seems likely that our results will be at least partially transferable to these contexts. ▪ There may have been differences between experts who agreed to participate and those who did not. However, we purposely interviewed experts from a range of backgrounds and public opinions about breast cancer screening.
for policy and practice, particularly if they persist and seem intractable. Relatively little is known about how breast screening experts develop different interpretations of the evidence on the benefits and harms of breast cancer screening. There have been a number of suggestions. Some attribute the differences to variable epidemiological understanding of potential biases. 12 16 17 Others acknowledge the possible effect of professional bias or vested interests, 6 12 17-19 or differing historically based assumptions about the biology or inevitability of cancer growth. 20 While these are all potentially relevant, it is likely that there are also deeper differences underlying the variation in experts' positions: that is, these experts may have different ideas about what is important and what matters with regard to breast screening 21 22 and/or the evaluation of evidence. 6 Well-meaning, thoughtful and epidemiologically competent experts may hold a range of views and ideas about breast cancer screening owing to differences in how they prioritise certain values or principles.
Values are integral to public health programme planning and are emphasised in the aims of many national breast-screening programmes including those of the UK, 23 Australia 24 and many European countries, 25 which refer to concepts such as delivering benefit, avoiding harm, accountability and recently, transparency and respect for autonomy. Many authors also see values as being important in the creation and interpretation of evidence. 26 27 Our commitment to different values may be expressed overtly, via debates and discussions about these values; but debates around such issues are rare in the literature on breast screening. This sidesteps important conversations about what is important and gives limited acknowledgement to the role of these values in determining breast-screening policy and practice decisions.
The idea that values are important in healthcare is not new. There has been considerable interest in paying attention to: patients' values in clinical practice 28 and health technology assessment; [29] [30] [31] citizens' values in healthcare policy; 32 33 and health practitioners' values in clinical practice. 34 35 This way of looking at healthcare not only assumes the importance of values in healthcare, 36 but also accepts a plurality of values among different stakeholders, and emphasises the need to explore and work through values' differences during healthcare decision-making. 35 With these ideas in mind, we aimed to investigate experts' values in breast screening, with a view to identifying new means by which persistent disagreements in this field might be understood or mitigated.
This study is part of a larger Australian National Health and Medical Research Council-funded project examining ethics and evidence in cancer screening. In this paper, we report on one component of a substudy focused on ethics and evidence in screening for breast cancer. Our aim in this paper is to empirically examine the values or principles that Australian experts employ when evaluating the Australian breast cancer screening programme. 37 We reasoned that by developing a clearer understanding of the values employed by these experts, we could move towards a better understanding of the debate about this changing and sometimes difficult topic. We focused on experts because (1) they are wellinformed relative to the general population of citizens, policymakers or researchers; (2) disagreement between experts has been a central feature of breast screening, so mapping experts' values should assist in understanding this disagreement and (3) these experts have influenced breast-screening policy and practice, both directly through decision-making bodies, and indirectly by influencing consumer groups and other policymakers. Our research questions were: ▸ What are the values expressed in the talk of Australian experts about breast screening in Australia? ▸ What are the implications for policy and practice of experts holding particular values?
METHOD Methodology
This study employed a qualitative methodology, with sampling, data collection and analysis strategies designed to best answer our research questions. 38 We used open qualitative methods because there was little pre-existing knowledge about the topic and because we sought to access the values of participants on their own terms. We were motivated by our commitment to empirical bioethics, in particular to the view that practice and theory must exist in a symbiotic relationship, where each has the potential to alter the other. 39 40 We undertook this study in that spirit, expecting that existing ethical theory would inform our analysis, but also that our data and analysis could make a useful contribution to ethical theorising in the area of breast screening. We have considerable experience and knowledge of grounded theory methodology, which informed our study design, 41 42 but this was not strictly a 'grounded theory study'. 43 44 Participants and sampling We selected participants from the population of 'influential experts', individuals who had engaged in frequent media commentary, publications, senior administration or management, advice to government or professional committees, or senior advocacy on breast screening. We sampled purposively for maximum variation 45 of ideas, deliberately inviting participants with strongly divergent opinions (table 1). We also reasoned that perspectives may be associated with professional responsibilities and experiences, so contacted participants with a range of professional roles.
We identified potential interviewees by scanning academic and popular media publications on breast screening, and personnel lists on websites of organisations involved in breast screening. We also followed up on suggestions from colleagues and previously interviewed experts. As experts, all participants were able to be contacted via information in the public domain.
We approached 46 experts via email, and interviewed 33 (17 male and 16 female). Thirteen people either refused (3), or were unable to participate (1), or did not respond to emails (9) . We had a particularly low response rate from volunteers who were on public record as holding senior roles in consumer advocacy organisations. This may have been due to a higher turnover of people in these positions than in other professional roles: they may no longer have been working as advocates when we sent our email. Our sampling evolved as analysis progressed, ensuring that we had enough representation of positions and roles to give us confidence in our findings. 41 We continued to sample until we reached thematic saturation.
38
Data collection LP conducted semistructured interviews face to face in the expert's or LP's workplace, or by telephone, if unavailable to meet in person, from October 2012 to October 2013. Interviews lasted 39-105 min (average 66 min). In keeping with reports from the literature, we found that face-to-face and telephone interviews were of comparable quality and length. 46 Utilising telephone interviews enabled us to interview experts across the country.
Interviews were designed to elicit experts' views and opinions on breast screening in Australia. LP described her interest in the topic as a medical practitioner undertaking doctoral studies in cancer-screening ethics. She noted aloud that there was an obvious range of opinions among experts despite, and often about, the large evidence base, and suggested that she was interested in exploring this further. The aim of the interviews was to ensure that participants could speak freely without experiencing any judgement regarding their views. We did not ask direct questions about abstract values or principles, instead we asked about interviewees' experience of the breast-screening programme and their views on what was good or bad and why (see online supplementary appendix). Interviews were digitally recorded, transcribed by a professional service, and de-identified.
Analysis
Analysis focused on developing a set of categories that captured the most important values in experts' talk. Our goal was not to develop a theory, but to identify midrange ethical concepts being used by participants, and understand what those concepts meant in use. Interviews were read repeatedly and coded in detail to capture values-in-use. From codes, more abstract categories were developed; these evolved iteratively as the data collection and analysis progressed. LP wrote analytic memos throughout, and shared these with other authors for discussion. Coding, categorisation and memo writing were closely informed by Charmaz's iteration of the constant comparative method. 41 All participants gave individual written or verbal consent, were assured of confidentiality, and were free to withdraw from the study at any stage.
RESULTS

Experts disagreed as to whether, or to what degree, values influenced their thinking
Although all experts discussed value-laden concepts in relation to breast screening, they varied in how much Epidemiologists/biostatisticians 9 (1) Not otherwise specified [NOS] 5 (1) Administrators/managers Administrators/ managers 6 (2) Advocacy leaders 6 (7) Consumers working in advocacy 3 (6) Clinicians/researchers working in advocacy 3 (1) Public stance on breast screening ‡ Supportive 16 (9) Mostly supportive § 3 (1) Critical 6 (0) Unknown to researchers 8 (3)
*Note that some experts held more than one professional role. †Most clinicians engaged in research to a greater or lesser extent. ‡We loosely categorised potential interviewees as being 'supportive', 'mostly supportive' or 'critical' about breast screening based on publicly available commentary. §Broadly supportive of breast screening but with selected concerns about one or more elements of the programme.
they considered values to be important in shaping their opinions. Many experts suggested that values influenced their thinking, volunteering that "ideology" (#15 epidemiologist), "values" (#17 researcher, not otherwise specified (NOS)) or "judgements" (#13 consumer advocate), as well as evidence, influenced how they and others formed opinions about breast screening. Others denied the influence of values, contrasting value-based reasoning (characterised by use of "intuition, judgement, political trickery, [and attending to] those with the loudest voice" (#29 epidemiologist) against scientific reasoning (in which, 'the figures cannot lie' #21 epidemiologist). For these experts, using values meant being biased or unscientific, and as such, should be avoided: "I'm a scientist, I look at the available evidence and I try and evaluate that impartially" (#9 oncologist).
A single expert presented a unique argument against using values when reasoning about breast screening. Using values, they argued, required deep, philosophical reflection. They saw themselves as a person of action rather than reflection, which meant values thinking was not relevant to them. This view suggested that values thinking was only for philosophers or academics, not for practitioners, and implied that practitioners could maintain a value-free position.
Experts invoked ethical and epistemological values in their talk
At the most abstract level, experts' value-talk about breast screening could be categorised into two main groups: ethical and epistemological ( Epistemological values related to preferred sources of knowledge, including the nature of evidence-based reasoning: Table 2 Experts' views on values that are important in breast cancer screening
Ethical values
The range of meanings-in-use of this value* (common conceptions of values are in italics)
Delivering benefits † Breast cancer-related benefits (mortality: reducing population breast cancer mortality; reducing breast cancer mortality in non-elderly women. Morbidity: enabling less aggressive treatments; providing reassurance; reducing population burden of disease-incidence of total/advanced breast cancer) Non-breast cancer-related benefits (reducing all-cause mortality; improving health for communities with the poorest health outcomes) Avoiding harms † Low overdiagnosis rate; low false positive rate; minimal overtreatment; minimal pain and inconvenience; low false negative rate (false reassurance) Respecting autonomy † Providing information; facilitating informed choice; providing screening to women in the target age range; providing screening upon request for older women beyond the target age; maximising breast screening participation so that women will have the knowledge to make decisions about their future Equity 47 of clinical medicine (delivering benefit, avoiding harm, respecting autonomy, supporting justice), as well as principles more commonly endorsed in public health practice or public health ethics (economic efficiency, accountability and fair and/or transparent decision-making processes). Experts also valued professionalism.
A range of epistemological values was also expressed (table 2), with experts describing ways of thinking about knowledge, including views on constructing or reviewing the scientific evidence base and uses of non-evidencebased knowledge. 48 Experts had different interpretations of value-related concepts Although experts' value talk reflected familiar ethical and epistemological concerns, our central finding is this: there was substantial variation in the way experts conceived of each value. This is consistent with the literature, which acknowledges and discusses such distinctions and complexities. 35 The range of ways that experts conceive of each value is shown in table 2. The most commonly discussed values were also the most variably constructed: we discuss this in detail below.
Delivering benefits
Experts' conceptions of delivering benefit in breast screening fell into two main categories: breast cancer-specific and non-breast cancer-specific outcomes. All experts talked about breast cancer-specific benefits, including reduced population breast cancer mortality and morbidity. Morbidity was mostly discussed in terms of enabling less aggressive treatment and reducing population breast cancer burden. Two experts (both consumer advocates) also included breast cancer-related reassurance:
Some of that benefit might be just peace of mind, the fact that you don't, as far as they can tell, have breast cancer. (#24 consumer advocate)
Most experts suggested that breast screening delivered modest to substantial population mortality benefits. Many also saw the breast cancer morbidity benefits of screening as substantial, but others saw them as being absent. Participants' conception of morbidity appeared to inform their perception of the presence or absence of this benefit. When participants said, 'screening offers morbidity benefits' they usually meant 'screening reduces the treatment needed, or provides reassurance'. When participants said, 'screening does not offer morbidity benefit' they usually meant, 'screening does not decrease the burden of breast cancer illness in populations' (generally because of the impact of overdiagnosis).
A small group of experts argued that breast screening did not deliver benefits. When they argued this, they used a broader, non-breast cancer-specific concept of benefits, and meant either that screening did not reduce all-cause mortality, or that screening did not assist the communities with the poorest health outcomes. These experts were concerned that the high cost and attention paid to breast screening meant that other, possibly more worthy, public health programmes were not implemented, meaning that the important public health benefit of improving health outcomes for the most needy was not realised.
Avoiding harms
Experts' described (avoiding) harm in a variety of ways (table 2), with two main patterns and a third minor pattern emerging. One group of experts, comprised mostly of researchers, conceived of harm as being mainly about overdiagnosis. A second group, mostly clinicians, saw significant harms in false-positive diagnoses and/or overtreatment. Not all researchers or clinicians expressed a clear conception of harm, and of those that did, not all described it along these lines. However, these two major patterns were associated with particular professional roles, suggesting some influence of availability bias. 49 Researchers whose work involved calculating overdiagnosis in populations tended to conceptualise harm as overdiagnosis. By contrast, clinicians working with identifiable patients receiving false-positive results and negotiating between appropriate treatment and overtreatment, tended to see harm in these terms. A third, less widely expressed view about harms concentrated on women's experience of the screening process. This view was held by all three consumer advocates and one researcher, who described harm in terms of minor physical discomfort and inconvenience, and denied that overdiagnosis or false positives caused harm:
Women aren't being harmed by breast screening and society isn't being harmed by breast screening. It's … a little mindset that has developed. (#13 consumer advocate)
As with benefits, we saw correlations between experts' concepts of harm and ideas about levels of harm. Those who viewed harm as overdiagnosis perceived harms as more extensive than those who viewed harm as false positives, overtreatment, or unpleasant experiences.
Respecting autonomy
Experts expressed differing versions of what respecting autonomy means in breast screening. The dominant view was that respecting autonomy is about providing comprehensive information to women who are offered breast screening. A less common view, described by a smaller number of experts, including all three consumer advocates, placed respecting autonomy as being about the provision and promotion of breast screening, as this enabled women to "find out whether you have [a cancer] or not" (#24 consumer advocate) early enough to enable less aggressive treatments. For these experts, information was less central to autonomy than the option/encouragement to screen. They advocated limiting information in order to avoid scaring women away.
Epistemological values
Most experts viewed the scientific evidence as the most important source of knowledge about breast cancer screening. There was a wide spread of ideas, however, about what constitutes 'good' scientific evidence (table 2), and this spread was evident across the subgroup of epidemiologists and biostatisticians. For example, some epidemiologists said it was important to consider all studies, others preferred only top-quality studies, some prioritised recent, local service studies, and there were differing opinions about mathematical models. Several experts emphasised their own studies when discussing examples of evidence that they used and trusted.
A smaller number of experts described their lack of understanding of the scientific evidence on breast screening. Some explained that they still viewed this evidence as important and relied on the interpretation of trusted colleagues or opinion leaders. Others, including two who openly stated that they did not trust the scientific evidence, described additional or different sources of knowledge (table 2) Experts' awareness about different interpretations Some experts were aware of variations in how values were conceived, occasionally referring to an alternative conception to their own, mainly in order to reject it. Discussion of such differences was not common, however, most experts expressed values implicitly rather than explicitly, and did not explore alternative meanings of the values they were using. This opens the possibility that experts may sometimes be speaking at crosspurposes about what is important in breast screening, despite using similar terminology.
Conflicting values
Many experts described a perceived conflict between one or more values in the breast-screening context. They saw certain values as being in tension with each other, such that respecting one value would necessarily entail sacrificing the other. Most experts who discussed conflicting values described tensions between respecting autonomy and delivering benefit. These experts equated respecting autonomy with providing information, and felt that providing information to consumers might reduce participation rates and, therefore, lower breast cancer mortality and morbidity benefits of screening. Some experts simply described a spectrum of positions that one could take regarding these conflicting values, such as 'the continuum between individual autonomy and public health' (#17 researcher NOS). Others openly favoured one value over another, with implications for practice. Those who prioritised delivering benefits, for example, preferred to limit breast-screening information in order to avoid frightening women away. Those who prioritised autonomy were in favour of providing more comprehensive information and encouraging informed choice.
A smaller number of experts discussed conflicting values in terms of avoiding harms and delivering benefits. Their view about the relative importance of these two values had practical implications for whether or not they supported breast screening: those who prioritised avoiding harm were less likely to support screening than those who prioritised delivering benefits. Experts' conceptions of harm were also important, however, and box 1 describes several examples of ways in which the combination of experts' conception and prioritisation of 'avoiding harm' might affect their level of support for breast screening.
As reported, experts rarely discussed alternative conceptions of a particular value different to their own. By contrast, experts frequently referred to alternative ways other experts might prioritise values. Several experts agreed that an important step towards resolving conflict in breast screening was to seek consensus on which values to prioritise.
DISCUSSION
We have shown that experts' positions in breast screening are influenced by more than just the evidence 50 ; they are also influenced by a wide range of ethical and epistemological values. We have demonstrated considerable variation in how experts conceive of individual values, and how they prioritise certain values over others. These differences, together with a lack of knowledge about how one might, or whether one should, engage in explicit values-based discussions, suggests a vast potential for fundamental disagreement about screening policies and programmes.
Disagreements in breast screening have persisted despite multiple meta-analyses of the breast-screening evidence, including the recent Independent Review led by Marmot.
14 This review made a vital contribution, providing a highly regarded consensus on quantification of mortality reduction and overdiagnosis. Its publication was, however, immediately followed by disputes about both the conclusions and their implications for policy and practice. 15 We noted earlier that differences of opinion of this sort are often attributed to the correctness or incorrectness of evidence interpretations, 12 16 17 but our findings suggest that evidence interpretations may also be related to variations in epistemological values. Other authors attribute disagreements to vested interests. 6 12 17-19 Although we did not explore experts' financial or commercial interests in this study, many participants had direct clinical and/or research interests in breast screening. Their familiarity with and trust in their own work may have led them to ignore or discount evidence that presented an alternative view. More significantly, our study suggests another, potentially more subtle set of reasons to explain differing opinions: experts may hold quite different values, or different versions of the same values. Even epidemiologically competent and non-conflicted experts may disagree about breast cancer screening because of deep value commitments. They may be working from very different understandings of what is good or bad about breast screening, what its goals should be, and what matters.
Strengths and limitations
The strengths of this study are its empirical nature and the completeness of its reach. This is, to the best of our knowledge, the first empirical ethics study with breastscreening policymakers and practitioners. We were able to interview a wide selection of key players in breast screening in Australia, and so could provide a comprehensive picture of experts' values and reasoning. Possible limitations include the focus on Australia, as experts from other jurisdictions may hold different values. However, since the Australian programme shares much in terms of rationale, purpose and implementation with counterpart programmes in the UK and many European countries, it seems likely that our results will be at least partially transferable. Note, that we were not seeking to demonstrate the prevalence of particular values (which would require a survey in a population-based sample), rather, we aimed to capture the range and variety of values. By continuing our sampling and analysis until we reached thematic saturation we are confident that we have achieved this aim. 38 Finally, it is possible that experts who agreed to take part were somehow different from those who did not, however, we sought to minimise such potential bias by ensuring that we interviewed experts from a range of backgrounds and professed opinions about screening.
Implications for practice, policy and research Our findings have strong implications for practice and policy, as both the way experts conceive of values, and the types of values they prioritise, directly influence the positions they take regarding breast screening. The current situation where values are rarely explicitly considered or discussed is not ideal. We do not presume that all experts should adhere to one set of 'correct' public health values, or even that such a thing exists. Rather we argue for a closer, more explicit examination of the values underpinning breast-screening service provision and policy by individual experts, in expert decision-making bodies, and in the public domain. 51 52 Our findings highlight several issues suitable for specific examination by breast-screening decision-makers, the public and researchers (box 2).
If stakeholders are able to be more transparent about values, this may enable people with seemingly divergent positions to recognise points of agreement, or at least improve their understanding of why others think the way they do, helping to build bridges between opposing viewpoints. It should also assist with the justification of breast-screening policy, and wider debate about concordance or discordance between the values of influential experts and the considered judgements of the community. 39 53 Empirical investigation of citizens' values regarding breast screening was beyond the scope of this project, but is an important issue for future research.
Broad engagement regarding what is important to experts and citizens (eg, by using a citizen's jury model 32 ) could support the development of an explicit framework of values to guide future decision-making on breast screening. 54 This would not be straightforward: the plurality and apparent incommensurability of values in communities is well recognised, such that it may be best not to expect or force a consensus, but rather to focus on the fairness of the decision-making process. 55 Regardless, Weed 56 reminds us that more engagement with and knowledge about ethics and values has a tendency to lead to more ethically appropriate decisions, and that this is a worthy aim in provision of healthcare and public health services.
Box 1 Conception of values and prioritisation of values influences experts' opinions on breast screening
The following three case study examples from the data illustrate how experts' conception and prioritisation of 'avoiding harm' can influence their opinions on breast screening. Expert A (#21 epidemiologist) saw breast-screening harm in terms of overdiagnosis and considered these harms to be substantial. This expert saw both avoiding harms and delivering benefits as being important, but because harms were, in their view, so large, was not supportive of the breast-screening programme. Expert B (#10 epidemiologist) saw breast-screening harms as being limited to those inconveniences that women experienced as a result of attending screening services: thus, they were seen as very minor. Thus, although this expert believed strongly that avoiding harms should take priority over delivering benefits in the context of public health programmes in general, the harms from breast screening were, in their view, so negligible they were strongly supportive of breast screening. Expert C (#9 oncologist) saw breast-screening harm in terms of overdiagnosis. This expert was uncertain as to the level of overdiagnosis harm: "you don't know how much to worry about that" but assumed it was, "probably lower that in some of the other screening programs." They thought delivering benefits should take priority over avoiding harms: "[Some] professionals may put a higher weight and value on 'first do no harm'. It's a point of view. It's not my point of view." Their overall opinion was, like Expert B but via a very different route, highly supportive of breast screening.
Engagement with values in breast screening-or any other area of health intervention-cannot be a once-only activity, as values change over time in expert and lay communities. For example, since organised breast screening began, consumer leaflets have become increasingly detailed and information rich, reflecting the generally increasing value given to promoting the autonomy of healthcare consumers. 57 Changes in epistemological values have also occurred, including the introduction of evidence-based medicine, 58 changed thinking about study quality, 59 and the growing attention to impartial reviews by independent experts. 13 14 Growing evidence about overdiagnosis has changed the way we think about and prioritise the value of avoiding harm. Research about values, and processes to incorporate values in policy setting and decision-making, will need to evolve and continue to reflect this ongoing change. Debates around ethical and epistemological values should sit alongside the regular discussions of evidence, as part of ongoing processes for planning the future of breast screening.
Contributors LP initiated and performed the study, and prepared the first and subsequent drafts of the paper. LR and SC assisted with study planning and data analysis, trained and supported LP in data collection and analysis methods, and made substantial contributions to draft revisions throughout. LP is the guarantor. Box 2 Examples of value-related topics that warrant further research and public debate ▸ Plurality of experience influencing values: Our study suggested a likely impact of availability bias on some experts' conceptions of values. Experts are likely to understand concepts such as harm, benefit and autonomy differently depending on what they encounter day to day (eg, population-level data, or individual women experiencing disease or the consequences of screening). We suggest that conversations and attempted definitions about values in breast screening should endeavour to include a plurality of professional roles and experiences in order to cover the likely range of conceptions of relevant values. ▸ Focus of population health programmes: Some participants in our study concentrated on the impact of breast screening on all-cause mortality or on the health of vulnerable populations, expressing concern that, in their view, breast screening had minimal impact on these, and that the programme was associated with substantial opportunity costs. This raises questions about the aim or focus of population health programmes, and indicates that there may be differences between people' opinions about exactly where that focus should lie. It would be useful to elucidate the range of relevant values on this issue. ▸ Breast cancer consumers' view of screening: Consumer advocates in this study presented a very particular view of breast screening. They emphasised morbidity benefits including reassurance; tended to suggest that harms were minimal; and argued that the best way to respect women's autonomy was to provide them with, and promote, screening services, as this allowed them to access information about their personal breast cancer risk. It seems possible that these ways of thinking about screening may risk generating 'too much medicine' 10 for women. We were only able to interview three consumer advocates, and as such our findings may not be indicative of the entire range of opinion in the breast cancer consumer movement. However, the experts that we spoke to were in senior consumer advocacy roles, and expressed remarkably consistent positions on each of these three important values. Further research is needed to explore the range of values held by consumer advocates. If our findings are transferable to breast cancer consumer advocacy more generally, it seems possible that these values may promote and protect screening activity, but provide little avenue for adjustment or improvement in line with new evidence and technologies. ▸ Professional ethics education: Opportunities to participate in training in thinking explicitly about ethics and values may assist experts in the difficult task of decision-making. 51 Thinking and talking about values is not easy, not least because-as we have shown-the same terminology can be used to communicate very different meanings. Explicit training has the potential to increase the robustness and contextualisation of reasoning about breast screening, both by individuals and in decision-making bodies. 39 53 
